Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (4): 330-333.DOI: 10.3969/j.issn.1673-8640.2020.04.010

• Orginal Article • Previous Articles     Next Articles

Retrospective analysis of common drugs' therapeutic drug monitoring results in patients with mental diseases

YU Aiping1, SUN Juanyu2, XIE Haiyan1, LU Wen1(), GUO Xiaoxia1, SHI Yun3   

  1. 1. Department of Clinical Laboratory,the Third Hospital of Quzhou,Quzhou 324000,Zhejiang,China
    2. Department of Life Sciences,Faculty of Sciences,University of Toronto,Toronto M5S2E8,Canada
    3. Department of Clinical Laboratory,Shanghai Mental Health Center,Shanghai Jiao Tong University,Shanghai 200030,China
  • Received:2019-08-03 Online:2020-04-30 Published:2020-05-19

Abstract:

Objective To study the role of therapeutic drug monitoring(TDM) by the retrospective analysis of 5 common drugs' TDM results in patients with mental diseases. Methodse The TDM results of 2 mood stabilizers(valproic acid,carbamazepine) and 3 antipsychotics(clozapine,olanzapine,palisperidone) in 721 patients with mental diseases were analyzed retrospectively,and the control rates of the 5 drugs before and after TDM were compared. Results The control rates of valproic acid and carbamazepine before TDM were 31.15% and 33.33%,while those after TDM increased to 81.53% and 81.82%,respectively. The control rates of clozapine,olanzapine and palisperidone before TDM were 24.35%,67.32% and 68.75%,while those after TDM increased to 62.61%,83.01% and 83.13%,respectively. Compared with before TDM,the control rates of the 5 drugs after TDM were increased(P<0.05). After TDM,the increase rate of valproic acid for the control rate(50.38%) was higher than those of clozapine,olanzapine and palisperidone(38.26%,15.69% and 14.38%,respectively)(P<0.05),while the increase rate of carbamazepine for the control rate(48.49%) was higher than those of olanzapine and palisperidone(15.69% and 14.38%,respectively)(P<0.05). Conclusions TDM can effectively guide clinical drug use,realize individual drug use and achieve optimal therapeutic effect.

Key words: Therapeutic drug monitoring, Schizophrenia, Bipolar disorder

CLC Number: